Caris Life Sciences has named Joachim Schorr to be its chief scientific officer.
Schorr formerly worked for two decades at Qiagen, where he was senior vice president of global research and development, managing director, and a member of the executive committee, among other positions. He will continue to serve as a scientific consultant for Qiagen.
Prior to joining Qiagen, Schorr worked at Hoechst, a German chemical-pharmaceuticals company, and was also co-founder of Coley Pharmaceuticals, EnPharma Pharmaceuticals, and QBM Cell Sciences. He holds a PhD in molecular biology and virology from the University of Cologne.
TrovaGene has appointed Mark Elander as chief scientific officer. Elander will direct the clinical development program for the company's portfolio of transrenal and urine-based molecular diagnostic assays. He will also oversee the ongoing clinical program for Trovagene's human papillomavirus carrier screening assay.
Elander previously served as chief scientific officer of BioTheranostics, a BioMérieux company. Prior to this, he was a research fellow at the RW Johnson Pharmaceutical Research Institute, part of Johnson & Johnson. He has also been a postdoctoral fellow in the department of molecular biology at Scripps Research Institute.
Nancy Kelley has stepped down from her post as founding executive director of the New York Genome Center. Kelley had been the driving force behind the center's creation and last November had also taken on the role of chief operating officer. She will continue to serve as an advisor and remain on the center's board of directors (IS 3/12/2013).